REGN - Regeneron Pharmaceuticals, Inc.
(NaN%)
SNP 500NASDAQ
Hold
Strong Growth but Declining
72%
based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 5.72%
Operating Income Growth is -5.87%
Net Income Growth is 16.62%
Earnings Per Share (EPS) Growth is 15.32%
Net Margin is 33.61%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 5.28
Debt Ratio is 0.22
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.05
Cash Flow is MODERATE
Cash from Operations Growth is -18.7%
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is Moderate
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Regeneron Pharmaceuticals, Inc. (REGN) - https://www.regeneron.com/
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Leonard Schleifer
Employees - 12,099
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2024 and future.
Know the Stock © 2024 and future.